UCB (OTCMKTS:UCBJF) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJF)’s share price gapped down prior to trading on Friday . The stock had previously closed at $322.94, but opened at $300.10. UCB shares last traded at $322.89, with a volume of 11 shares.

Analyst Ratings Changes

A number of research firms recently issued reports on UCBJF. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research note on Monday, December 8th. Stephens reissued an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Finally, Barclays reaffirmed an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, UCB has a consensus rating of “Buy”.

UCB Stock Performance

The business has a 50-day moving average of $295.76 and a two-hundred day moving average of $268.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.